Alison L. Hannah
Equibles does not estimate personal net worth.
About Alison L. Hannah
Alison L. Hannah was last confirmed as Board Member at Neogenomics Inc (NEO) in a filing dated April 15, 2020. CytomX Therapeutics, Inc. reported in an 8-K filed July 13, 2022 that Alison L. Hannah was terminated as SVP, Chief Medical Officer, effective September 30, 2022. The proxy statement of CytomX Therapeutics, Inc. reports total compensation of $1,707,176 for Alison L. Hannah in fiscal 2021, including a base salary of $464,400. Disclosed compensation is on record for 4 fiscal years.
“the employment of Carlos Campoy, the Company's SVP, Chief Financial Officer, and Alison Hannah, M.D., the Company's SVP, Chief Medical Officer, is expected to terminate effective as of September 30, 2022”
Affiliation history
-
Start not stated–2020-04-15
Last confirmed by a filing; no departure on record
-
CytomX Therapeutics, Inc. (CTMX)
Proxy statement
Start not stated–2022-09-30
Company network
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2021 | CytomX Therapeutics, Inc. (CTMX) | Senior Vice President and Chief Medical Officer | $464,400 | $1,707,176 |
| 2020 | CytomX Therapeutics, Inc. (CTMX) | Senior Vice President and Chief Medical Officer | $412,500 | $1,677,988 |
| 2019 | CytomX Therapeutics, Inc. (CTMX) | Senior Vice President and Chief Medical Officer | — | — |
| 2018 | CytomX Therapeutics, Inc. (CTMX) | Senior Vice President and Chief Medical Officer | — | — |